Abdel-Meguid et al., “An orally bioavaiable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis,” Biochemistry, 33(39):11671-11677 (1994). |
Ashkenazi et al., “Safety and antitumor activity of recombinant soluble Apo2 lignad,” J Clinical Investigation, 104(2):155-162 (1999). |
Durso et al., “The antimitotic tripeptide hemiasterlin,” Pro Am Assoc Cancer Res Annual Meeting, vol. 40, p. 286, Mar. 1999. |
Erickson et al., “Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibior complexed to HIV-1 protease,” Science, 249(4968):527-533 (1990). |
Gamble et al., “Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein,” Science, 278:849-853 (1997). |
Grannelli-Piperno et al., “Efficient Interaction of HIV-1 with Purified Dendritic Cells via multiple chemokine Coreceptors,” J Exp Med, 184:2433-2438 (1996). |
Hall et al., “Substituted 4-hydroxyproline di-and tri-peptides as cytoxic agents,” Amino Acids, 16(1):79-89 (1999). |
Henderson et al., “Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: postranslational modifications, proteolytic processing, and complete amino acid sequences,” Journal of Virology, 66(4):1856-1865 (1992). |
Hwang et al., “Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1,” Science, 253:71-74 (1991). |
Kowalski et al., “Functional regions of the envelope glycoprotein of human immunodeficiency virus type I,” Science, 237:1351-1355 (1987). |
Lassila et al., “A Role for Lys-His-Gly-NH2 in Avian and Murine B Cell Development,” Cell. Immun., 122:319-328, (1989). |
Louis et al., “Hydrophilic peptides derived from the transframe region of GaPol inhibit the HIV-1 protease,” Biochemistry, 37(8):2105-2110 (1998). |
Martin, “Fast-acting slow viruses,” Nature, 345:572-573 (1990). |
Memar O. et al., “Antiviral Agents in Dermatology; Current Status and Future Prospects,” Internation Journal of Dermatology, 34(9):597-606 (1995). |
Miller et al., “Antiviral activity of carbobenzoxy Di-and Tripeptides on measles virus,” Applied Microbiology, 16(10):1489-1496 (1968). |
Niedrig et al., “Inhibition of Infectious human immunodeficiency virus type 1 particles formation by Gag protein derived peptides,” Journal of General Virology, 75:1469-1474 (1994). |
Palker et al., “Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides,” Proc. Natl. Acad. Sci. USA, 85(6):1932-1936 (1988). |
Richards, “Inhibition of the aspartic proteinase for HIV-2,” FEBS Letters, 253(1,2):214-216 (1989). |
Sheha et al., “Synthesis of di-and tripeptide analogues containing α-ketoamide as a new core structure for inhibition of HIV-1 protease,” Eur. J. Med. Chem., 35(10):887-894 (2000). |
Sigma, Peptide and Amino Acid Catalog, p. 27 and p. 70, Copyright 1995-96. |
Su et al., “The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1,” Journal of Human Virology, 4(1):1-7 (2001). |
Su et al., “The tripeptide glycl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication,” Journal of Human Virology, 4(1):8-15 (2001). |
Vahlne, “Protein Polymerization Inhibitors and Methods of Use,” U.S. patent application Ser. No. 10/072,783, filed Feb. 8, 2002. |
Van Der Spoel et al., “Pentamer Peptide Amide, ALGPGNH2, which Inhibits Viral Infectivity and Methods of Use Thereof,” U.S. patent application Ser. No. 10/217,933, filed Aug. 12, 2002. |
Goobar-Larsson et al., “Molecules that Block Viral Infectivity and Methods of Use Thereof,” U.S. patent application Ser. No. 10/217,933, filed Sep. 3, 2002. |
Bachem Catalog, Bachem Bioscience Inc. 1993, pp. 28, 29, 34, 145, 267 ,332 ,333 ,457 ,535 ,536 ,541 , 546 and 553. |